Cargando…

Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs

BACKGROUND: The objective of this study was to assess the potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement (P&R) process with regard to orphan drugs. METHODS: A four step approach was designed. Firstly, a systematic lite...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kolasa, Katarzyna, Zwolinski, Krzysztof M., Kalo, Zoltan, Hermanowski, Tomasz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4787054/ https://www.ncbi.nlm.nih.gov/pubmed/26965710 http://dx.doi.org/10.1186/s13023-016-0388-0

Ejemplares similares

Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis
por: Kolasa, Katarzyna, et al.
Publicado: (2018)

Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs
por: Schey, C., et al.
Publicado: (2017)

A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
por: de Andrés-Nogales, Fernando, et al.
Publicado: (2021)

Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011)

Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals – an application on improving tender decision making in Indonesia
por: Inotai, Andras, et al.
Publicado: (2018)

A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt
por: Elezbawy, Baher, et al.
Publicado: (2022)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)

Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut)
por: Guarga, Laura, et al.
Publicado: (2019)

Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs—a Systematic Literature Review. Next Steps in Methodology Development?
por: Baran-Kooiker, Aleksandra, et al.
Publicado: (2018)

Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison
por: Lee, Jong Hyuk
Publicado: (2021)

Using Multiple Criteria Decision Analysis (MCDA) to make coverage decisions: a methodological framework
por: Kanavos, Panos, et al.
Publicado: (2015)

Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016
por: Drake, Julia I., et al.
Publicado: (2017)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Addressing Uncertainties in Planning Sustainable Systems Through Multi-criteria Decision Analysis (MCDA)
por: Tapia, John Frederick D., et al.
Publicado: (2023)

Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?
por: Jommi, Claudio, et al.
Publicado: (2021)

Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries
por: Zelei, Tamás, et al.
Publicado: (2016)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

A multicriteria decision analysis (MCDA) tool to purchase implantable medical devices in Egypt
por: Elezbawy, Baher, et al.
Publicado: (2022)

Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
por: Paulden, Mike, et al.
Publicado: (2014)

Priority setting in the Brazilian emergency medical service: a multi-criteria decision analysis (MCDA)
por: Frazão, Talita D. C., et al.
Publicado: (2021)

Case studies for implementing MCDA for tender and purchasing decisions in hospitals in Indonesia and Thailand
por: Holtorf, Anke-Peggy, et al.
Publicado: (2021)

The reimbursement coverage decisions and pricing rules for medical devices in Taiwan
por: Tsai, Hsin-Yi, et al.
Publicado: (2022)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
por: Elvira, David, et al.
Publicado: (2023)

Drug pricing and reimbursement information management: processes and decision making in the global economy
por: Tsourougiannis, Dimitrios
Publicado: (2017)

Multi–Criteria–Decision–Analysis (MCDA) for the Horizon Scanning of Health Innovations an Application to COVID 19 Emergency
por: Ruggeri, Matteo, et al.
Publicado: (2020)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Applying Multiple Criteria Decision Analysis (MCDA) in the context of HTA: an experimental case study on metastatic colorectal cancer
por: Angelis, Aris, et al.
Publicado: (2015)

Reimbursement of orphan drugs in Belgium: what (else) matters?
por: Picavet, Eline, et al.
Publicado: (2014)

Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
por: van den Brink, Rinke
Publicado: (2014)

Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA)
por: Wahlster, Philip, et al.
Publicado: (2015)

Strengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analysis (MCDA)
por: Rutten-van Mölken, Maureen, et al.
Publicado: (2018)

Physician pricing and health insurance reimbursement
por: Yett, Donald E., et al.
Publicado: (1983)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion
por: Detiček, Andreja, et al.
Publicado: (2018)

Exploring the opinions and experiences of patients with generic substitution: a representative study of Polish society
por: Drozdowska, Aleksandra, et al.
Publicado: (2014)

Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework
por: Campolina, Alessandro Gonçalves, et al.
Publicado: (2022)

Recommendation for a Pilot MCDA Tool to Support the Value-Based Purchasing of Generic Medicines in the UAE
por: Farghaly, Mohamed Naser, et al.
Publicado: (2021)

A systematic review of moral reasons on orphan drug reimbursement
por: Zimmermann, Bettina M., et al.
Publicado: (2021)

Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs
por: Iskrov, Georgi, et al.
Publicado: (2016)

Pricing and reimbursement of novel oncology drugs in Sweden
por: Haglund, Mattias, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cmahhvt241fuggbcbhpklmpo3u